Objective: To investigate the molecular alterations of splenocytes associated with anti-factor Ⅷ (FⅧ) immune response and the underlying mechanisms based on hemophilia A (HA) murine model via RNA sequencing (RNA-seq) technology.
Methods: Severe HA mice were immunized with recombinant human factor Ⅷ (rhF8) weekly for 4 weeks to establish an FⅧ inhibitor model. High quality raw data were obtained by using bulk RNA-seq and CASAVA base identification technology, and the differentially expressed genes (DEGs) were identified. The DEGs were statistically classified by gene ontology (GO) annotation to obtain information on the major signaling pathways and biological processes involved in anti-FⅧ immune response in HA mouse splenocytes. The cell clusters, genes, and signaling pathway datasets were comprehensively analyzed by GO, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and single cell RNA-seq (ScRNA-seq) analysis, respectively. Flow cytometry analysis was used to verify the changes in T follicular helper cells (Tfh) and regulatory T cells (Treg).
Results: A total of 3731 DEGs was identified, including 2275 genes with up-regulated expression and 1456 genes with down-regulated expression. The DEGs were enriched in helper T cell differentiation, cytokine receptor, T cell receptor signaling pathway, ferroptosis, etc. Uniform Manifold Approximation and Project (UMAP) downscaling and visualization analysis yielded a total number of 11 T/NK cell subsets, visualizing the overall expression distribution of C-X-C chemokine-specific receptor gene cxcr5 among these T/NK cell subsets. Higher expression of cxcr5 was found in activated Tfh from FⅧ inhibitor mice, in comparison to the control group. The visualization using Upset plot R language showed a close interaction between Tfh and Treg. Moreover, the increased frequencies of Tfh and the decreased frequencies of Treg in inhibitor mouse splenocytes were further verified by flow cytometry analysis.
Conclusion: Multiple immune cell subsets, signaling pathways, and characteristic genes may be involved in the process of anti-FⅧ immune response in HA mouse splenocytes. The molecules involved in the regulation of Tfh/Treg may play key roles, which provide potential biological targets and therapeutic strategies for HA patients with inhibitors in the future.
{"title":"[RNA Sequencing Reveals Molecular Alternations of Splenocytes Associated with Anti-FⅧ Immune Response in Hemophilia A Murine Model].","authors":"Chen-Chen Wang, Ya-Li Wang, Yuan-Hua Cai, Qiao-Yun Zheng, Zhen-Xing Lin, Ying-Yu Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.035","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.035","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the molecular alterations of splenocytes associated with anti-factor Ⅷ (FⅧ) immune response and the underlying mechanisms based on hemophilia A (HA) murine model via RNA sequencing (RNA-seq) technology.</p><p><strong>Methods: </strong>Severe HA mice were immunized with recombinant human factor Ⅷ (rhF8) weekly for 4 weeks to establish an FⅧ inhibitor model. High quality raw data were obtained by using bulk RNA-seq and CASAVA base identification technology, and the differentially expressed genes (DEGs) were identified. The DEGs were statistically classified by gene ontology (GO) annotation to obtain information on the major signaling pathways and biological processes involved in anti-FⅧ immune response in HA mouse splenocytes. The cell clusters, genes, and signaling pathway datasets were comprehensively analyzed by GO, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis and single cell RNA-seq (ScRNA-seq) analysis, respectively. Flow cytometry analysis was used to verify the changes in T follicular helper cells (Tfh) and regulatory T cells (Treg).</p><p><strong>Results: </strong>A total of 3731 DEGs was identified, including 2275 genes with up-regulated expression and 1456 genes with down-regulated expression. The DEGs were enriched in helper T cell differentiation, cytokine receptor, T cell receptor signaling pathway, ferroptosis, etc. Uniform Manifold Approximation and Project (UMAP) downscaling and visualization analysis yielded a total number of 11 T/NK cell subsets, visualizing the overall expression distribution of C-X-C chemokine-specific receptor gene <i>cxcr5</i> among these T/NK cell subsets. Higher expression of <i>cxcr5</i> was found in activated Tfh from FⅧ inhibitor mice, in comparison to the control group. The visualization using Upset plot R language showed a close interaction between Tfh and Treg. Moreover, the increased frequencies of Tfh and the decreased frequencies of Treg in inhibitor mouse splenocytes were further verified by flow cytometry analysis.</p><p><strong>Conclusion: </strong>Multiple immune cell subsets, signaling pathways, and characteristic genes may be involved in the process of anti-FⅧ immune response in HA mouse splenocytes. The molecules involved in the regulation of Tfh/Treg may play key roles, which provide potential biological targets and therapeutic strategies for HA patients with inhibitors in the future.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1476-1485"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.009
Ran Huang, Yuan-Bing Wu, Ya-Xue Wu, Xiao-Hui Hu
Objective: To analyze the clinical features of acute myeloid leukemia patients with DEK-NUP214 fusion gene positive.
Methods: The DEK-NUP214 fusion gene was amplified by multi-nested PCR in 26 patients admitted to the First Affiliated Hospital of Soochow University from January 2018 to October 2023, and the disease course and post-transplant survival data were obtained by searching outpatient and inpatient medical records and telephone follow-up.
Results: The median follow-up time of pateints was 21.25(0.9-60.2) months. Among 26 patients with DEK-NUP214 fusion gene positive AML, 15 patients had FLT3-ITD gene mutation positive. One patient died after abandoning treatment due to non-remission of induction chemotherapy, one died due to infection, and 23 patients received allo-HSCT after achieving CR, of which one patient died within one month after transplantation due to multiple infections and one died due to severe pulmonary infection that did not respond to treatment. One patient received allo-HSCT in non-remission state and later died due to recurrence.
Conclusion: DEK-NUP214 fusion gene positive AML is a type of acute leukemia subtype with high risk and poor prognosis. Allo-HSCT treatment at the early stage of disease remission is the most effective way to improve the prognosis of patients.
{"title":"[Characterization of Acute Myeloid Leukemia Patients with <i>DEK-NUP214</i> Fusion Gene Positive].","authors":"Ran Huang, Yuan-Bing Wu, Ya-Xue Wu, Xiao-Hui Hu","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.009","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.009","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the clinical features of acute myeloid leukemia patients with <i>DEK-NUP214</i> fusion gene positive.</p><p><strong>Methods: </strong>The <i>DEK-NUP214</i> fusion gene was amplified by multi-nested PCR in 26 patients admitted to the First Affiliated Hospital of Soochow University from January 2018 to October 2023, and the disease course and post-transplant survival data were obtained by searching outpatient and inpatient medical records and telephone follow-up.</p><p><strong>Results: </strong>The median follow-up time of pateints was 21.25(0.9-60.2) months. Among 26 patients with <i>DEK-NUP214</i> fusion gene positive AML, 15 patients had <i>FLT3-ITD</i> gene mutation positive. One patient died after abandoning treatment due to non-remission of induction chemotherapy, one died due to infection, and 23 patients received allo-HSCT after achieving CR, of which one patient died within one month after transplantation due to multiple infections and one died due to severe pulmonary infection that did not respond to treatment. One patient received allo-HSCT in non-remission state and later died due to recurrence.</p><p><strong>Conclusion: </strong><i>DEK-NUP214</i> fusion gene positive AML is a type of acute leukemia subtype with high risk and poor prognosis. Allo-HSCT treatment at the early stage of disease remission is the most effective way to improve the prognosis of patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1293-1298"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.033
Yu-Xian Wang, Hao Xiong, Zhi Chen, Li Yang, Fang Tao, Yu DU, Zhuo Wang, Ming Sun, Shan-Shan Qi, Lin-Lin Luo
Objective: To investigate the clinical features and risk factors associated with cutaneous chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children.
Methods: A retrospective analysis was conducted on the clinical data of children who underwent allo-HSCT in the Wuhan Children's Hospital from August 1, 2016, to December 31, 2023, and were regularly followed up for 1 year or more. The differences in clinical features between children with and without cutaneous cGVHD were compared, and the risk factors affecting the occurrence of cutaneous cGVHD were analyzed.
Results: During the study period, 296 children received allo-HSCT. Until December 31, 2024, follow-up showed that 20 children (6.8%) developed cutaneous cGVHD, which manifested as cutaneous lichenification, hyperpigmentation, keratosis pilaris, sclerotic changes, and hair or nail involvement. According to their skin lesion area and degree of grading, 5 cases were mild, 10 cases were moderate, and 5 cases were severe. Multivariate logistic regression analysis revealed that female donors and previous acute GVHD were risk factors for the development of cutaneous cGVHD after allo-HSCT. All 20 children were treated with glucocorticoid ± calcineurin inhibitors (tacrolimus/cyclosporine) as first-line therapeutic agents. Only 1 child improved after first-line treatment. The remaining 19 children treated with a second-line regimen of combination interventions based on individualized status, including 10 children who could not tolerate hormonotherapy or first-line treatment, and showed no significant improvement after 3 months, as well as 9 children with multi-organ cGVHD. After comprehensive second-line treatment, 17 children showed improvement in cutaneous symptoms. There were 3 deaths, including 1 due to primary disease recurrence and 2 due to pulmonary infections.
Conclusion: The skin is the first manifestation and most common organ involved in cGVHD in children. Cutaneous cGVHD severely affects the daily activities of transplanted children and requires prolonged immunosuppressive therapy, but has a favorable prognosis. First-line treatments for adults are not applicable to children who usually require a combination treatment with multiple drugs.
{"title":"[Clinical Analysis of Cutaneous Chronic Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation in Childhood].","authors":"Yu-Xian Wang, Hao Xiong, Zhi Chen, Li Yang, Fang Tao, Yu DU, Zhuo Wang, Ming Sun, Shan-Shan Qi, Lin-Lin Luo","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.033","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.033","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical features and risk factors associated with cutaneous chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of children who underwent allo-HSCT in the Wuhan Children's Hospital from August 1, 2016, to December 31, 2023, and were regularly followed up for 1 year or more. The differences in clinical features between children with and without cutaneous cGVHD were compared, and the risk factors affecting the occurrence of cutaneous cGVHD were analyzed.</p><p><strong>Results: </strong>During the study period, 296 children received allo-HSCT. Until December 31, 2024, follow-up showed that 20 children (6.8%) developed cutaneous cGVHD, which manifested as cutaneous lichenification, hyperpigmentation, keratosis pilaris, sclerotic changes, and hair or nail involvement. According to their skin lesion area and degree of grading, 5 cases were mild, 10 cases were moderate, and 5 cases were severe. Multivariate logistic regression analysis revealed that female donors and previous acute GVHD were risk factors for the development of cutaneous cGVHD after allo-HSCT. All 20 children were treated with glucocorticoid ± calcineurin inhibitors (tacrolimus/cyclosporine) as first-line therapeutic agents. Only 1 child improved after first-line treatment. The remaining 19 children treated with a second-line regimen of combination interventions based on individualized status, including 10 children who could not tolerate hormonotherapy or first-line treatment, and showed no significant improvement after 3 months, as well as 9 children with multi-organ cGVHD. After comprehensive second-line treatment, 17 children showed improvement in cutaneous symptoms. There were 3 deaths, including 1 due to primary disease recurrence and 2 due to pulmonary infections.</p><p><strong>Conclusion: </strong>The skin is the first manifestation and most common organ involved in cGVHD in children. Cutaneous cGVHD severely affects the daily activities of transplanted children and requires prolonged immunosuppressive therapy, but has a favorable prognosis. First-line treatments for adults are not applicable to children who usually require a combination treatment with multiple drugs.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1461-1467"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.044
Yu-Jie Qin, Hai-Song Lu, Wei-Min Cheng
Ferroptosis initiates membrane oxidative damage through lipid peroxidation and iron accumulation, and accumulates reactive oxygen species (ROS) during aplastic anemia (AA). Ferroptosis induces damage and apoptosis of hematopoietic stem/progenitor cells, mesenchymal stem cells, blood cells, and T lymphocytes through various pathways, inhibits bone marrow hematopoiesis, damages bone marrow microenvironment, exacerbates immune imbalance, leading to bone marrow failure and disease progression. Therefore, further exploring the ferroptosis mechanism in AA can help clarify the pathogenesis of disease and provide new research ideas and directions for the treatment of AA.
{"title":"[The mechanism of Ferroptosis in Aplastic Anemia --Review].","authors":"Yu-Jie Qin, Hai-Song Lu, Wei-Min Cheng","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.044","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.044","url":null,"abstract":"<p><p>Ferroptosis initiates membrane oxidative damage through lipid peroxidation and iron accumulation, and accumulates reactive oxygen species (ROS) during aplastic anemia (AA). Ferroptosis induces damage and apoptosis of hematopoietic stem/progenitor cells, mesenchymal stem cells, blood cells, and T lymphocytes through various pathways, inhibits bone marrow hematopoiesis, damages bone marrow microenvironment, exacerbates immune imbalance, leading to bone marrow failure and disease progression. Therefore, further exploring the ferroptosis mechanism in AA can help clarify the pathogenesis of disease and provide new research ideas and directions for the treatment of AA.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1538-1541"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To analyze the correlation between the expression levels of Tim-3, C-myc and the proportion of T lymphocyte subsets and prognosis in patients with acute lymphoblastic leukemia (ALL).
Methods: The research group selected 60 ALL patients admitted to our hospital from December 2019 to December 2021, while the control group selected 55 healthy volunteers who underwent physical examination in our hospital. The expression levels of Tim-3, C-myc mRNA and the proportion of T lymphocyte subsets in the two groups were detected. The mortality rate of ALL patients was calculated, and the correlation between the expression levels of Tim-3, C-myc, and the proportion of T lymphocyte subsets and pathological features and prognosis was analyzed.
Results: Compared with the control group, the levels of Tim-3, C-myc and CD8+ in the research group were increased, while the levels of CD3+ , CD4+ and CD4+ /CD8+ were decreased (all P < 0.001). The levels of Tim-3, C-myc mRNA, CD3+ , CD4+ , CD8+ , CD4+ /CD8+ were correlated with risk classification and extramedullary infiltration (all P < 0.05). The survival rate of patients with low expression of Tim-3, C-myc, and CD8+ was higher than that of patients with high expression, while the survival rate of patients with high expression of CD3+ , CD4+ , and CD4+ /CD8+ was higher than that of patients with low expression (all P < 0.05). Univariate analysis showed that the deceased patients had higher proportions of extramedullary infiltration and high-risk classification, as well as higher levels of Tim-3, C-myc, and CD8+ , while lower levels of CD3+ , CD4+ , and CD4+ /CD8+ compared with surviving patients (all P < 0.01). Multivariate logistic regression analysis showed that extramedullary invasion, risk classification, Tim-3, C-myc, CD3+ , CD4+ , CD8+ , CD4+ /CD8+ were the main factors affecting the prognosis of ALL patients (all P < 0.05). ROC curve analysis showed that the combination of Tim-3, C-myc, and T lymphocyte subsets had higher sensitivity and accuracy in predicting prognosis of ALL patients compared with the single diagnosis of Tim-3, C-myc, CD3+ , CD4+ , CD8+ , and CD4+ /CD8+ (P < 0.05).
Conclusion: ALL patients show higher levels of Tim-3, C-myc mRNA and CD8+ but lower levels of CD3+ , CD4+ and CD4+/CD8+. Moreover, the expression levels of Tim-3, C-myc, CD3+ , CD4+ , CD8+ and CD4
{"title":"[Correlation between Expression Levels of Tim-3, <i>C-myc</i> and Proportion of T Lymphocyte Subsets and Prognosis in Patients with Acute Lymphoblastic Leukemia].","authors":"Yu-Chai Zhong, Ke-Ding Hu, Yi-Rong Jiang, Xiao-Wen Huang","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.010","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.010","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the correlation between the expression levels of Tim-3, <i>C-myc</i> and the proportion of T lymphocyte subsets and prognosis in patients with acute lymphoblastic leukemia (ALL).</p><p><strong>Methods: </strong>The research group selected 60 ALL patients admitted to our hospital from December 2019 to December 2021, while the control group selected 55 healthy volunteers who underwent physical examination in our hospital. The expression levels of Tim-3, <i>C-myc</i> mRNA and the proportion of T lymphocyte subsets in the two groups were detected. The mortality rate of ALL patients was calculated, and the correlation between the expression levels of Tim-3, <i>C-myc</i>, and the proportion of T lymphocyte subsets and pathological features and prognosis was analyzed.</p><p><strong>Results: </strong>Compared with the control group, the levels of Tim-3, <i>C-myc</i> and CD8<sup>+</sup> in the research group were increased, while the levels of CD3<sup>+</sup> , CD4<sup>+</sup> and CD4<sup>+</sup> /CD8<sup>+</sup> were decreased (all <i>P</i> < 0.001). The levels of Tim-3, <i>C-myc</i> mRNA, CD3<sup>+</sup> , CD4<sup>+</sup> , CD8<sup>+</sup> , CD4<sup>+</sup> /CD8<sup>+</sup> were correlated with risk classification and extramedullary infiltration (all <i>P</i> < 0.05). The survival rate of patients with low expression of Tim-3, <i>C-myc</i>, and CD8<sup>+</sup> was higher than that of patients with high expression, while the survival rate of patients with high expression of CD3<sup>+</sup> , CD4<sup>+</sup> , and CD4<sup>+</sup> /CD8<sup>+</sup> was higher than that of patients with low expression (all <i>P</i> < 0.05). Univariate analysis showed that the deceased patients had higher proportions of extramedullary infiltration and high-risk classification, as well as higher levels of Tim-3, <i>C-myc</i>, and CD8<sup>+</sup> , while lower levels of CD3<sup>+</sup> , CD4<sup>+</sup> , and CD4<sup>+</sup> /CD8<sup>+</sup> compared with surviving patients (all <i>P</i> < 0.01). Multivariate logistic regression analysis showed that extramedullary invasion, risk classification, Tim-3, <i>C-myc</i>, CD3<sup>+</sup> , CD4<sup>+</sup> , CD8<sup>+</sup> , CD4<sup>+</sup> /CD8<sup>+</sup> were the main factors affecting the prognosis of ALL patients (all <i>P</i> < 0.05). ROC curve analysis showed that the combination of Tim-3, <i>C-myc</i>, and T lymphocyte subsets had higher sensitivity and accuracy in predicting prognosis of ALL patients compared with the single diagnosis of Tim-3, <i>C-myc</i>, CD3<sup>+</sup> , CD4<sup>+</sup> , CD8<sup>+</sup> , and CD4<sup>+</sup> /CD8<sup>+</sup> (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>ALL patients show higher levels of Tim-3, <i>C-myc</i> mRNA and CD8<sup>+</sup> but lower levels of CD3<sup>+</sup> , CD4<sup>+</sup> and CD4<sup>+</sup>/CD8<sup>+</sup>. Moreover, the expression levels of Tim-3, <i>C-myc</i>, CD3<sup>+</sup> , CD4<sup>+</sup> , CD8<sup>+</sup> and CD4<su","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1299-1304"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.045
Wei-Lin Liu, Chun-Yi Lyu, Teng Wang, Chen Han, Rui-Rong Xu
E3 ubiquitin ligase is a key enzyme that determines substrate specificity during ubiquitination and plays an important role in regulating the degradation of tumor suppressor or oncogenic proteins. E3 ubiquitin ligase is involved in regulating leukemia cell differentiation, cell cycle and immune response, and it is closely related to the occurrence and development of acute myeloid leukemia (AML). Targeting highly specific E3 ubiquitin ligase can be used as an effective treatment for AML. This article reviewed the latest progress of E3 ubiquitin ligase in the diagnosis and treatment of AML, aiming to provide insights for the precise targeted therapy of this disease.
{"title":"[Latest Research Progress of E3 Ubiquitin Ligase in the Diagnosis and Treatment of Acute Myeloid Leukemia --Review].","authors":"Wei-Lin Liu, Chun-Yi Lyu, Teng Wang, Chen Han, Rui-Rong Xu","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.045","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.045","url":null,"abstract":"<p><p>E3 ubiquitin ligase is a key enzyme that determines substrate specificity during ubiquitination and plays an important role in regulating the degradation of tumor suppressor or oncogenic proteins. E3 ubiquitin ligase is involved in regulating leukemia cell differentiation, cell cycle and immune response, and it is closely related to the occurrence and development of acute myeloid leukemia (AML). Targeting highly specific E3 ubiquitin ligase can be used as an effective treatment for AML. This article reviewed the latest progress of E3 ubiquitin ligase in the diagnosis and treatment of AML, aiming to provide insights for the precise targeted therapy of this disease.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1542-1545"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.011
Xiao-Ying Yang, Bo Tang, Hui-Hui Liu, Wei-Wei Xie, Shuang-Lian Xie, Wen-Qiong Wang, Jin Wang, Shan Zhao, Yu-Jun Dong
Objective: To screen anti-tumor drugs that improve antigen processing and presentation in acute myeloid leukemia (AML) cells.
Methods: A TCR-like or TCR mimic antibody that can specifically recognize HLA-A*0201:WT1126-134 ( RMFPNAPYL) complex (hereafter referred to as HLA-A2:WT1) was synthesized to evaluate the function of antigen processing and presentation machinery (APM) in AML cells. AML cell line THP1 was incubated with increasing concentrations of IFN-γ, hypomethylating agents (HMA), immunomodulatory drugs (IMiD), proteasome inhibitors (PI) and γ-secretase inhibitors (GSI), followed by measuring of HLA-ABC, HLA-A2 and HLA-A2:WT1 levels by flow cytometry at consecutive time points.
Results: The TCR-like antibody we generated only binds to HLA-A*0201+WT1+ cells, indicating the specificity of the antibody. HLA-A2:WT1 level of THP-1 cells detected with the TCR-like antibody was increased significantly after co-incubation with IFN-γ, showing that the HLA-A2:WT1 TCR like antibody could evaluate the function of APM. Among the anti-tumor agents screened in this study, GSI (LY-411575) and HMA (decitabine and azacitidine) could significantly increase the HLA-A2:WT1 level. The IMiD lenalidomide and pomalidomide could aslo upregulate the expression of HLA-A2:WT1 complex under certain concentrations of the drugs and incubation time. As proteasome inhibitors, carfilzomib could significantly decreased the expression of HLA-A2:WT1, while bortezomib had no significant effect on HLA-A2:WT1 expression.
Conclusion: HLA-A2:WT1 TCR-like antibody can effectively reflect the APM function. Some of the anti-tumor drugs can affect the APM function and immunogenicity of tumor cells.
{"title":"[Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody].","authors":"Xiao-Ying Yang, Bo Tang, Hui-Hui Liu, Wei-Wei Xie, Shuang-Lian Xie, Wen-Qiong Wang, Jin Wang, Shan Zhao, Yu-Jun Dong","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.011","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.011","url":null,"abstract":"<p><strong>Objective: </strong>To screen anti-tumor drugs that improve antigen processing and presentation in acute myeloid leukemia (AML) cells.</p><p><strong>Methods: </strong>A TCR-like or TCR mimic antibody that can specifically recognize HLA-A*0201:WT1<sub>126-134</sub> ( <i>RMFPNAPYL</i>) complex (hereafter referred to as HLA-A2:WT1) was synthesized to evaluate the function of antigen processing and presentation machinery (APM) in AML cells. AML cell line THP1 was incubated with increasing concentrations of IFN-γ, hypomethylating agents (HMA), immunomodulatory drugs (IMiD), proteasome inhibitors (PI) and γ-secretase inhibitors (GSI), followed by measuring of HLA-ABC, HLA-A2 and HLA-A2:WT1 levels by flow cytometry at consecutive time points.</p><p><strong>Results: </strong>The TCR-like antibody we generated only binds to HLA-A*0201<sup>+</sup>WT1<sup>+</sup> cells, indicating the specificity of the antibody. HLA-A2:WT1 level of THP-1 cells detected with the TCR-like antibody was increased significantly after co-incubation with IFN-γ, showing that the HLA-A2:WT1 TCR like antibody could evaluate the function of APM. Among the anti-tumor agents screened in this study, GSI (LY-411575) and HMA (decitabine and azacitidine) could significantly increase the HLA-A2:WT1 level. The IMiD lenalidomide and pomalidomide could aslo upregulate the expression of HLA-A2:WT1 complex under certain concentrations of the drugs and incubation time. As proteasome inhibitors, carfilzomib could significantly decreased the expression of HLA-A2:WT1, while bortezomib had no significant effect on HLA-A2:WT1 expression.</p><p><strong>Conclusion: </strong>HLA-A2:WT1 TCR-like antibody can effectively reflect the APM function. Some of the anti-tumor drugs can affect the APM function and immunogenicity of tumor cells.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1305-1311"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.027
Wen Wu, Xin-Ping Zhang, Xiang-Yan Huang
Objective: To study the characteristics of a novel variant of the α-1,3-N-acetylgalactosaminyltransferase gene in a family through serological and gene sequence analyses of a proband with ABO subtype and her family members.
Methods: Blood samples of the proband and four family members were collected. The ABO phenotypes were detected by serological methods, and the ABO blood group genotyping was performed by fluorescence PCR. Direct sequencing was carried out for exons 1-7 of the ABO gene in the proband and family members, and cloning sequencing was conducted for exons 6 and 7.
Results: The serological test showed that the blood group phenotype of the proband was Ael type, and the ABO blood group genotyping result was A/O. Sequencing results indicated that on the basis of the ABO*A1.01 sequence, there were simultaneous variations of c.467C>T and c.664G>A in exon 7 of the A allele, which belonged to a novel variation of the A allele and had been registered in GenBank with the accession number MZ076784.1. Family investigation revealed that the proband, her son and granddaughter all had this novel variation.
Conclusion: On the basis of the ABO*A1.01 sequence, the new variation of the combination of c.467C>T and c.664G>A in exon 7 is a heritable variation. It is speculated that this variation is the cause of the weakened expression of the A antigen.
目的:通过对1例ABO亚型先显子及其家族成员的血清学和基因序列分析,研究α-1,3- n -乙酰半乳糖氨基转移酶基因新变异的特征。方法:采集先证者及4名家庭成员的血液样本。采用血清学方法检测ABO表型,荧光PCR检测ABO血型基因分型。先证者及家族成员ABO基因外显子1-7直接测序,外显子6、7克隆测序。结果:血清学检测显示先证者血型表型为Ael型,ABO血型基因分型结果为A/O。测序结果显示,在ABO*A1.01序列的基础上,A等位基因第7外显子存在c.467C>T和c.664G>A的同时变异,属于A等位基因的新变异,已在GenBank中登记,登录号为MZ076784.1。家庭调查显示,先证者、她的儿子和孙女都有这种新颖的变异。结论:在ABO*A1.01序列的基础上,第7外显子c.467C>T与c.664G>A组合的新变异为可遗传变异。推测这种变异是导致A抗原表达减弱的原因。
{"title":"[A Study of a New Variation of α-1, 3-N-acetylgalactosaminyltransferase Gene in Pedigrees].","authors":"Wen Wu, Xin-Ping Zhang, Xiang-Yan Huang","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.027","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.027","url":null,"abstract":"<p><strong>Objective: </strong>To study the characteristics of a novel variant of the α-1,3-N-acetylgalactosaminyltransferase gene in a family through serological and gene sequence analyses of a proband with ABO subtype and her family members.</p><p><strong>Methods: </strong>Blood samples of the proband and four family members were collected. The ABO phenotypes were detected by serological methods, and the ABO blood group genotyping was performed by fluorescence PCR. Direct sequencing was carried out for exons 1-7 of the ABO gene in the proband and family members, and cloning sequencing was conducted for exons 6 and 7.</p><p><strong>Results: </strong>The serological test showed that the blood group phenotype of the proband was Ael type, and the ABO blood group genotyping result was A/O. Sequencing results indicated that on the basis of the <i>ABO*A1.01</i> sequence, there were simultaneous variations of c.467C>T and c.664G>A in exon 7 of the A allele, which belonged to a novel variation of the A allele and had been registered in GenBank with the accession number MZ076784.1. Family investigation revealed that the proband, her son and granddaughter all had this novel variation.</p><p><strong>Conclusion: </strong>On the basis of the <i>ABO*A1.01</i> sequence, the new variation of the combination of c.467C>T and c.664G>A in exon 7 is a heritable variation. It is speculated that this variation is the cause of the weakened expression of the A antigen.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1418-1421"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.19746/j.cnki.issn.1009-2137.2025.05.036
Dan Su, Liu-Ming Sun, Wan-Hui Li, Xiao-Qian Lyu
Objective: To explore the role of semaphorin 4D (Sema4D) in immunoglobulin A (IgA) -mediated immune abnormalities in B lymphocytes of pediatric Henoch-Schonlein purpura (HSP).
Methods: One hundred HSP children admitted to Hengshui People's Hospital from January 2022 to January 2023 were selected as HSP group, and one hundred healthy children as control group. Sema4D expression was detected, and the relationship between Sema4D expression in children's serum and skin lesions and clinical characteristics of children was analyzed. Sema4D expression on the surface of lymphocytes of HSP children was detected. Different concentrations of human recombinant Sema4D protein was used to stimulate peripheral blood mononuclear cells in HSP children in vitro. The expression level of IgA in the supernatant was detected to verify whether Sema4D mediates immune abnormalities through IgA secreted by B lymphocytes.
Results: The Sema4D level in the HSP group was significantly higher than that in the control group (P <0.001). Sema4D level in HSP children with severe, renal involvement, and joint involvement was higher than those with mild to moderate disease, and no renal or joint involvement (all P <0.001). Compared with control group, IgA level, CD8 + T lymphocyte proportion, and CD19 + B lymphocyte proportion in the HSP group were significantly higher but CD4 + T lymphocyte proportion was lower (all P <0.001). The expression levels of Sema4D on the surface of CD4 + T lymphocytes, CD8 + T lymphocytes, and CD19 + B lymphocytes in the HSP group were significantly higher than those in the control group (all P <0.001). With the increase of human recombinant Sema4D protein concentration, the level of IgA expression in HSP children gradually increased (P <0.05). Correlation analysis showed that Sema4D was significantly positively correlated with IgA (r =0.667).
Conclusion: HSP children show high expression of Sema4D, especially on the surface of T and B lymphocytes. The shedding of Sema4D from membrane surface may stimulate B lymphocytes to secrete IgA by binding to CD72, leading to immune abnormalities.
目的:探讨信号蛋白4D (Sema4D)在免疫球蛋白A (IgA)介导的儿童过敏性紫癜(HSP) B淋巴细胞免疫异常中的作用。方法:选择2022年1月至2023年1月在衡水市人民医院住院的HSP患儿100例作为HSP组,健康儿童100例作为对照组。检测Sema4D表达,分析儿童血清和皮肤病变中Sema4D表达与儿童临床特征的关系。检测HSP患儿淋巴细胞表面Sema4D表达。采用不同浓度的人重组Sema4D蛋白体外刺激HSP患儿外周血单个核细胞。检测上清中IgA的表达水平,验证Sema4D是否通过B淋巴细胞分泌IgA介导免疫异常。结果:HSP组Sema4D水平显著高于对照组(P + T淋巴细胞比例、CD19 + B淋巴细胞比例显著高于对照组),CD4 + T淋巴细胞比例显著低于对照组(P + T淋巴细胞、CD8 + T淋巴细胞、CD19 + B淋巴细胞均显著高于对照组(P P r =0.667)。结论:HSP患儿Sema4D高表达,尤其在T淋巴细胞和B淋巴细胞表面表达。Sema4D从膜表面脱落可能刺激B淋巴细胞结合CD72分泌IgA,导致免疫异常。
{"title":"[The Role of Sema4D in Immune Abnormalities Mediated by IgA Secreted by B Lymphocytes in Children with Henoch-Schonlein Purpura].","authors":"Dan Su, Liu-Ming Sun, Wan-Hui Li, Xiao-Qian Lyu","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.036","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.036","url":null,"abstract":"<p><strong>Objective: </strong>To explore the role of semaphorin 4D (Sema4D) in immunoglobulin A (IgA) -mediated immune abnormalities in B lymphocytes of pediatric Henoch-Schonlein purpura (HSP).</p><p><strong>Methods: </strong>One hundred HSP children admitted to Hengshui People's Hospital from January 2022 to January 2023 were selected as HSP group, and one hundred healthy children as control group. Sema4D expression was detected, and the relationship between Sema4D expression in children's serum and skin lesions and clinical characteristics of children was analyzed. Sema4D expression on the surface of lymphocytes of HSP children was detected. Different concentrations of human recombinant Sema4D protein was used to stimulate peripheral blood mononuclear cells in HSP children in vitro. The expression level of IgA in the supernatant was detected to verify whether Sema4D mediates immune abnormalities through IgA secreted by B lymphocytes.</p><p><strong>Results: </strong>The Sema4D level in the HSP group was significantly higher than that in the control group (<i>P</i> <0.001). Sema4D level in HSP children with severe, renal involvement, and joint involvement was higher than those with mild to moderate disease, and no renal or joint involvement (all <i>P</i> <0.001). Compared with control group, IgA level, CD8 <sup>+</sup> T lymphocyte proportion, and CD19 <sup>+</sup> B lymphocyte proportion in the HSP group were significantly higher but CD4 <sup>+</sup> T lymphocyte proportion was lower (all <i>P</i> <0.001). The expression levels of Sema4D on the surface of CD4 <sup>+</sup> T lymphocytes, CD8 <sup>+</sup> T lymphocytes, and CD19 <sup>+</sup> B lymphocytes in the HSP group were significantly higher than those in the control group (all <i>P</i> <0.001). With the increase of human recombinant Sema4D protein concentration, the level of IgA expression in HSP children gradually increased (<i>P</i> <0.05). Correlation analysis showed that Sema4D was significantly positively correlated with IgA (<i>r</i> =0.667).</p><p><strong>Conclusion: </strong>HSP children show high expression of Sema4D, especially on the surface of T and B lymphocytes. The shedding of Sema4D from membrane surface may stimulate B lymphocytes to secrete IgA by binding to CD72, leading to immune abnormalities.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1486-1490"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Photodynamic therapy has become an important method in clinical tumor treatment. This study aimed to investigate the effects of hematoporphyrin on multiple myeloma (MM) and its potential applications.
Methods: The MM cell line RPMI 8226 was treated with hematoporphyrin derivative (HPD), and CCK-8 assay was used to determine cell viability, apoptosis was detected by flow cytometry, intracellular reactive oxygen species (ROS) levels were measured using a detection kit combined with flow cytometry, and Western blot assay was used to detect apoptosis-related proteins and key signaling pathway protein levels.
Results: The optimal incubation time for the maximum absorption of HPD in RPMI 8226 cells was 4 hours. HPD significantly inhibited the proliferation of RPMI 8226 cells in a dose- and illumination time-dependent manner ( r =0.981; r =0.961). Additionally, HPD induced apoptosis in RPMI 8226 cells, but had no significant inhibitory effect on peripheral blood mononuclear cells derived from healthy individuals. HPD combined with illumination treatment significantly increased the intracellular ROS level, upregulated the expression of apoptosis-related proteins such as cleaved PARP, cleaved caspase-3 and Bax, and down-regulated the expression of proteins that maintain cell survival, such as NF-κB and Akt.
Conclusion: The HPD can inhibit the proliferation and induce apoptosis of multiple myeloma cells.
{"title":"[The Applications of Hematoporphyrin in the Treatment of Multiple Myeloma].","authors":"Jin-Xing Wang, Xiu-Juan Huang, Qian Zou, Peng-Wei Zhang, Wei Zhu, Fa-Qing Tian","doi":"10.19746/j.cnki.issn.1009-2137.2025.05.020","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.05.020","url":null,"abstract":"<p><strong>Objective: </strong>Photodynamic therapy has become an important method in clinical tumor treatment. This study aimed to investigate the effects of hematoporphyrin on multiple myeloma (MM) and its potential applications.</p><p><strong>Methods: </strong>The MM cell line RPMI 8226 was treated with hematoporphyrin derivative (HPD), and CCK-8 assay was used to determine cell viability, apoptosis was detected by flow cytometry, intracellular reactive oxygen species (ROS) levels were measured using a detection kit combined with flow cytometry, and Western blot assay was used to detect apoptosis-related proteins and key signaling pathway protein levels.</p><p><strong>Results: </strong>The optimal incubation time for the maximum absorption of HPD in RPMI 8226 cells was 4 hours. HPD significantly inhibited the proliferation of RPMI 8226 cells in a dose- and illumination time-dependent manner ( <i>r</i> =0.981; <i>r</i> =0.961). Additionally, HPD induced apoptosis in RPMI 8226 cells, but had no significant inhibitory effect on peripheral blood mononuclear cells derived from healthy individuals. HPD combined with illumination treatment significantly increased the intracellular ROS level, upregulated the expression of apoptosis-related proteins such as cleaved PARP, cleaved caspase-3 and Bax, and down-regulated the expression of proteins that maintain cell survival, such as NF-κB and Akt.</p><p><strong>Conclusion: </strong>The HPD can inhibit the proliferation and induce apoptosis of multiple myeloma cells.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 5","pages":"1374-1379"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}